Adriamycin and Ifosfamide Combined With Sintilimab

PHASE2RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

July 30, 2026

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Sintilimab plus chemotherapy

AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.

DRUG

Adriamycin-based chemotherapy

AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.

Trial Locations (1)

510060

RECRUITING

Xing Zhang, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER